Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
3.150
-0.230 (-6.80%)
Mar 31, 2025, 3:29 PM EDT - Market open
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 29 employees as of December 31, 2023. The number of employees increased by 8 or 38.10% compared to the previous year.
Employees
29
Change (1Y)
8
Growth (1Y)
38.10%
Revenue / Employee
n/a
Profits / Employee
-$894,072
Market Cap
119.43M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 29 | 8 | 38.10% |
Dec 31, 2022 | 21 | 0 | - |
Dec 31, 2021 | 21 | 9 | 75.00% |
Dec 31, 2019 | 12 | 0 | - |
Dec 31, 2018 | 12 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EPRX News
- 10 days ago - Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - PRNewsWire
- 4 weeks ago - Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - PRNewsWire
- 5 weeks ago - Eupraxia Pharmaceuticals Announces CFO Succession - PRNewsWire
- 4 months ago - Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months - PRNewsWire
- 4 months ago - Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting - PRNewsWire
- 4 months ago - Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024 - PRNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - PRNewsWire
- 5 months ago - Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results - PRNewsWire